{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:31:49Z","timestamp":1791311509763,"version":"4.3.1"},"reference-count":200,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":2328,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:p>Tumor necrosis factor\u2010\u03b1 (TNF\u2010\u03b1) is a proinflammatory cytokine involved in a wide range of important physiologic processes. This cytokine has a pathologic role in some diseases, and TNF\u2010\u03b1 antagonists are effective in treating inflammatory conditions. Given the putative role of TNF\u2010\u03b1 in host defense against tuberculosis and other infections, the risk of infection with TNF\u2010\u03b1 antagonists is a concern. Therefore, we searched the literature for reports of tuberculosis and other infections associated with TNF\u2010\u03b1\u2013antagonist therapy. Although tuberculosis was rarely reported in randomized clinical comparisons of these antagonists, case reports and submissions to the MedWatch program of the United States Food and Drug Administration have been numerous. Most instances were associated with infliximab, but etanercept and adalimumab may also be associated with an increased risk of tuberculosis. Histoplasmosis, listeriosis, aspergillosis, coccidioidomycosis, and candidiasis have been associated with TNF\u2010\u03b1 antagonists, but the causative relationship is not clear. Potential recipients of these drugs should be rigorously screened with skin testing, detailed questioning about recent travel and potential tuberculosis exposure, assessment for symptoms such as cough and weight loss, and chest radiography to minimize their risk of acquiring or reactivating tuberculosis. As with other immunosuppressant drugs, TNF\u2010\u03b1 antagonists should not be given to patients with active infection.<\/jats:p>","DOI":"10.1592\/phco.2005.25.9.1181","type":"journal-article","created":{"date-parts":[[2005,10,10]],"date-time":"2005-10-10T04:51:02Z","timestamp":1128919862000},"page":"1181-1192","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Infections Associated with Tumor Necrosis Factor\u2010\u03b1 Antagonists"],"prefix":"10.1002","volume":"25","author":[{"given":"David J.","family":"Rychly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"DiPiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1385\/IR:27:2-3:529"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200306000-00002"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200007133430207"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF\u2010\u03b1 regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach DR","year":"2002","journal-title":"J Immunol"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90001-2"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"ii37","DOI":"10.1136\/ard.62.suppl_2.ii37","article-title":"Role of tumor necrosis factor (TNF\u2010\u03b1) in host defense against tuberculosis: implications for immunotherapies targeting TNF","volume":"63","author":"Ehlers S.","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.7.3394"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.1.234"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90134-C"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00198530"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432201"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.4.311"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70332-X"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.511"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.11.1280"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.suppl_2.ii51"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20146"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11155"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05294.x"},{"issue":"3","key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"iii55","DOI":"10.1136\/ard.60.90003.iii55","article-title":"Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences","volume":"60","author":"Kraetsch HG","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20206"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50145"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4081\/monaldi.2004.712","article-title":"Difficult diagnosis of infliximab\u2010related miliary tuberculosis","volume":"61","author":"Contini S","year":"2004","journal-title":"Monaldi Arch Chest Dis"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-004-0873-z"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh074"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-1867-z"},{"key":"e_1_2_1_31_2","first-page":"1657","article-title":"Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid","volume":"30","author":"Ruiz Parra J","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg158"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01205-6"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/030097402317255372"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.2.231"},{"key":"e_1_2_1_36_2","first-page":"625","article-title":"Tuberculosis and treatment with infliximab [letter]","volume":"346","author":"Myers A","year":"2002","journal-title":"N Engl J Med"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200202213460815"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)01035-X"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03836.x"},{"key":"e_1_2_1_40_2","unstructured":"United States Food and Drug Administration.Safety update on TNF\u2010\u03b1 antagonists: infliximab and etanercept. Available fromwww.fda.govohrmsdocketsac01briefing3779b2_01_cber_safety20_revision2.pdf. AccessedAugust 25 2004."},{"key":"e_1_2_1_41_2","first-page":"526","article-title":"Mycobacteria tuberculosis peritonitis associated with etanercept therapy [letter]","volume":"21","author":"Manadan AM","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/421494"},{"key":"e_1_2_1_43_2","unstructured":"Centers for Disease Control and Prevention.Tuberculosis associated with blocking agents against tumor necrosis factor\u2010\u03b1: California 2002\u20132003. Morbidity and mortality weekly report.August 5 2004. Available fromwww.cdc.govmmwrpreviewmmwrhtmlmm5330a4.htm. Accessed January 25 2005."},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018085"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20123"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.7.998"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000077913.60364.D2"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04954-0"},{"key":"e_1_2_1_50_2","first-page":"841","article-title":"Chimeric anti\u2010tumor necrosis factor\u2010\u03b1 monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy","volume":"27","author":"Kavanaugh A","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05246-0"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90628-9"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70005-3"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03612.x"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.7.680"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.047"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20009"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.9.829"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(03)00406-8"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.06064.x"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.9.822"},{"key":"e_1_2_1_64_2","first-page":"7","article-title":"Infliximab for Crohn's disease in clinical practice: the experience of a single center in Romania","volume":"12","author":"Gheorghe L","year":"2003","journal-title":"Rom J Gastroenterol"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.006775"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1572-0241.2003.04009.x"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014258"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2002.004879"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11201"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01686.x"},{"key":"e_1_2_1_71_2","first-page":"952","article-title":"Clinical outcome of Crohn's disease treated with infliximab","volume":"50","author":"Arslan S","year":"2003","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07343.x"},{"key":"e_1_2_1_73_2","first-page":"760","article-title":"Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study","volume":"30","author":"Salvarani C","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-002-0246-3"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10671"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.10.1126"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(02)80038-X"},{"key":"e_1_2_1_78_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120472"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.6.631"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01268.x"},{"key":"e_1_2_1_81_2","first-page":"667","article-title":"Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis","volume":"29","author":"Shergy WJ","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200203000-00002"},{"key":"e_1_2_1_83_2","first-page":"118","article-title":"Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti\u2010tumor necrosis factor\u2010alpha monoclonal antibody infliximab","volume":"29","author":"Brandt J","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W"},{"key":"e_1_2_1_85_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01092.x"},{"key":"e_1_2_1_86_2","first-page":"1605","article-title":"Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis","volume":"28","author":"Stone M","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_1_87_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.3780070507"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.3780070505"},{"key":"e_1_2_1_89_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04089.x"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03263.x"},{"key":"e_1_2_1_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70224-6"},{"key":"e_1_2_1_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90277-5"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1159\/000080075"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1086\/383317"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"key":"e_1_2_1_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20299"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20221"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000124490.27666.B2"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20019"},{"key":"e_1_2_1_103_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.12.1627"},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11325"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017"},{"key":"e_1_2_1_107_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.4.437"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10308"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012664"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.8.1044"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432201"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003163421103"},{"issue":"6","key":"e_1_2_1_115_2","first-page":"S69","article-title":"Etanercept and methotrexate combination therapy","volume":"17","author":"Bankhurst AD.","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00004"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400401"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20300"},{"key":"e_1_2_1_119_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016451"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04034.x"},{"issue":"3","key":"e_1_2_1_121_2","first-page":"531","article-title":"Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti\u2010tumor necrosis factor\u2010alpha fusion receptor protein etanercept","volume":"31","author":"Brandt J","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:DDAS.0000011827.87103.2e"},{"key":"e_1_2_1_123_2","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sj\u00f6gren's syndrome: a pilot study","volume":"31","author":"Zandbelt MM","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_1_124_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.1.177"},{"key":"e_1_2_1_125_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11142"},{"key":"e_1_2_1_126_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10885"},{"key":"e_1_2_1_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00082-6"},{"key":"e_1_2_1_128_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0479-6"},{"key":"e_1_2_1_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00201-6"},{"key":"e_1_2_1_130_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10231"},{"key":"e_1_2_1_131_2","doi-asserted-by":"publisher","DOI":"10.1002\/art1.10243"},{"key":"e_1_2_1_132_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2252"},{"key":"e_1_2_1_133_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402356"},{"key":"e_1_2_1_134_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H"},{"key":"e_1_2_1_135_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.04705.x"},{"key":"e_1_2_1_136_2","first-page":"1238","article-title":"Long\u2010term safety and efficacy of etanercept in patients with rheumatoid arthritis","volume":"28","author":"Moreland LW","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_1_137_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O"},{"key":"e_1_2_1_138_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F"},{"key":"e_1_2_1_139_2","first-page":"360","article-title":"Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis","volume":"28","author":"Kietz DA","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_1_140_2","first-page":"732","article-title":"A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis","volume":"18","author":"Yazici Y","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_1_141_2","first-page":"101","article-title":"Anti\u2010tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland","volume":"71","author":"Cairns AP","year":"2002","journal-title":"Ulster Med J"},{"key":"e_1_2_1_142_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.2.171"},{"key":"e_1_2_1_143_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.4.410"},{"key":"e_1_2_1_144_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ICL.0000092064.05514.04"},{"key":"e_1_2_1_145_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.4.372"},{"key":"e_1_2_1_146_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740410005467"},{"key":"e_1_2_1_147_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"e_1_2_1_148_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.013052"},{"key":"e_1_2_1_149_2","first-page":"2563","article-title":"Adalimumab, a fully human anti\u2010tumor necrosis factor\u2010alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (safety trial of adalimumab in rheumatoid arthritis)","volume":"30","author":"Furst DE","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_1_150_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.009563"},{"key":"e_1_2_1_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80164-9"},{"key":"e_1_2_1_152_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"e_1_2_1_153_2","first-page":"2288","article-title":"A single dose, placebo controlled study of the fully human anti\u2010tumor necrosis factor\u2010alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis","volume":"29","author":"Broeder A","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_1_154_2","unstructured":"United States Food and Drug Administration.Adalimumab product approval information page. Available fromwww.fda.govcderbiologicsreviewadalabb123102r1p5.pdfAccessedAugust 25 2004."},{"key":"e_1_2_1_155_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10583"},{"key":"e_1_2_1_156_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10758"},{"key":"e_1_2_1_157_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20454"},{"key":"e_1_2_1_158_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200407000-00017"},{"key":"e_1_2_1_159_2","first-page":"2517","article-title":"Disseminated primary varicella infection during infliximab treatment","volume":"31","author":"Vonkeman H","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_1_160_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2720"},{"key":"e_1_2_1_161_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1040563"},{"key":"e_1_2_1_162_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200409000-00025"},{"key":"e_1_2_1_163_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200409000-00024"},{"key":"e_1_2_1_164_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20639"},{"key":"e_1_2_1_165_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11151"},{"key":"e_1_2_1_166_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1185-6"},{"key":"e_1_2_1_167_2","first-page":"606","article-title":"Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel","volume":"49","author":"Shrestha RK","year":"2004","journal-title":"Respir Care"},{"key":"e_1_2_1_168_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D151"},{"key":"e_1_2_1_169_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.006270"},{"key":"e_1_2_1_170_2","doi-asserted-by":"publisher","DOI":"10.1086\/377235"},{"key":"e_1_2_1_171_2","doi-asserted-by":"publisher","DOI":"10.1086\/502250"},{"key":"e_1_2_1_172_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11019"},{"key":"e_1_2_1_173_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200206-563OC"},{"key":"e_1_2_1_174_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.81"},{"key":"e_1_2_1_175_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200212000-00018"},{"key":"e_1_2_1_176_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10374"},{"key":"e_1_2_1_177_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.8.951"},{"key":"e_1_2_1_178_2","first-page":"1561","article-title":"Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab","volume":"29","author":"True DG","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_1_179_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-002-0925-9"},{"key":"e_1_2_1_180_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441415"},{"key":"e_1_2_1_181_2","first-page":"1663","article-title":"Septic arthritis caused by Actinobacillus ureae in a patient with rheumatoid arthritis receiving anti\u2010tumor necrosis factor\u2010alpha therapy","volume":"31","author":"Kaur PP","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_1_182_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540310017474"},{"key":"e_1_2_1_183_2","doi-asserted-by":"publisher","DOI":"10.2106\/00004623-200311000-00023"},{"key":"e_1_2_1_184_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0705-2"},{"key":"e_1_2_1_185_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000055092.90609.e5"},{"key":"e_1_2_1_186_2","doi-asserted-by":"publisher","DOI":"10.4065\/76.6.653"},{"key":"e_1_2_1_187_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.idc.0000138941.29168.38"},{"key":"e_1_2_1_188_2","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona L","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_1_189_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20009"},{"key":"e_1_2_1_190_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/141.2.347"},{"key":"e_1_2_1_191_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000127594.92432.7c"},{"key":"e_1_2_1_192_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(02)00101-1"},{"key":"e_1_2_1_193_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11301"},{"key":"e_1_2_1_194_2","unstructured":"National Institute of Allergy and Infectious Diseases National Institutes of Health.Tuberculosis.March 2002. Available fromwww.niaid.nih.govfactsheetstb.htm. Accessed August 25 2004."},{"key":"e_1_2_1_195_2","unstructured":"World Health Organization.Tuberculosis. Available fromwww.who.intmediacentrefactsheetsfs104en. AccessedAugust 25 2004."},{"key":"e_1_2_1_196_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00060-6"},{"key":"e_1_2_1_197_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00196-8"},{"key":"e_1_2_1_198_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00545-0"},{"key":"e_1_2_1_199_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2004.01.003"},{"issue":"4","key":"e_1_2_1_200_2","first-page":"S221","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"161","author":"Anonymous.","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_1_201_2","doi-asserted-by":"publisher","DOI":"10.1086\/421499"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.2005.25.9.1181","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.2005.25.9.1181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:09:57Z","timestamp":1761059397000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.2005.25.9.1181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":200,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1592\/phco.2005.25.9.1181"],"URL":"https:\/\/doi.org\/10.1592\/phco.2005.25.9.1181","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}